| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
On the basis of intestinal GLP-1 action that potentiates glucose-induced insulin release, incretin-based medicines have been widely used to treat type 2 diabetic patients. Gastric hormone ghrelin, in contrast, attenuates GLP-1-potentiated insulin release and GLP-1 release. GLP-1 and ghrelin are released in a reciprocal pattern. Therefore, the increased ghrelin/GLP-1 ratio in preprandial periods effectively prevents hypoglycemia and induces appetite. In contrast, the decreased ghrelin/GLP-1 ratio in postprandial periods effectively induces satiety and promotes disposal of elevated blood glucose. The interplay of ghrelin and GLP-1 may play a role in the systemic control of feeding and glucose metabolism, providing a novel strategy to treat type 2 diabetes with impaired insulin release and obesity with hyperphagia.
|
